43.26
Kodiak Sciences Inc stock is traded at $43.26, with a volume of 878.25K.
It is up +5.26% in the last 24 hours and up +27.01% over the past month.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
See More
Previous Close:
$41.10
Open:
$41.1
24h Volume:
878.25K
Relative Volume:
1.17
Market Cap:
$2.71B
Revenue:
-
Net Income/Loss:
$-230.66M
P/E Ratio:
-10.36
EPS:
-4.1742
Net Cash Flow:
$-148.12M
1W Performance:
+12.95%
1M Performance:
+27.01%
6M Performance:
+50.89%
1Y Performance:
+736.75%
Kodiak Sciences Inc Stock (KOD) Company Profile
Name
Kodiak Sciences Inc
Sector
Industry
Phone
650-281-0850
Address
1250 PAGE MILL RD, PALO ALTO, CA
Compare KOD vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
KOD
Kodiak Sciences Inc
|
43.26 | 2.57B | 0 | -230.66M | -148.12M | -4.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.31 | 121.89B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
656.12 | 69.52B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
859.43 | 54.49B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
184.97 | 39.11B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
281.26 | 38.46B | 4.29B | 577.22M | 641.34M | 4.2086 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-25-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Sep-22-25 | Initiated | Jefferies | Buy |
| Aug-14-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| Dec-11-23 | Resumed | Goldman | Sell |
| Nov-17-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Jul-25-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jul-25-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jul-24-23 | Downgrade | Jefferies | Buy → Hold |
| Nov-15-22 | Initiated | CapitalOne | Overweight |
| Aug-02-22 | Downgrade | Citigroup | Neutral → Sell |
| Feb-24-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-11-22 | Initiated | Goldman | Buy |
| Feb-02-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-12-21 | Initiated | Evercore ISI | Outperform |
| Mar-01-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-17-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Nov-30-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-03-20 | Initiated | Goldman | Buy |
| Feb-18-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-06-20 | Initiated | SunTrust | Buy |
| Jan-08-20 | Initiated | ROTH Capital | Buy |
| Jan-03-20 | Initiated | Jefferies | Buy |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-20-19 | Initiated | Chardan Capital Markets | Buy |
| Oct-29-18 | Initiated | Barclays | Overweight |
| Oct-29-18 | Initiated | BofA/Merrill | Buy |
| Oct-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Kodiak Sciences Inc Stock (KOD) Latest News
Why Did KOD Stock Surge To A Four-Year High Today? - Stocktwits
KOD News | KODIAK SCIENCES INC (NASDAQ:KOD) - ChartMill
Price to earnings forward of Kodiak Sciences, Inc. – LS:A2N6P0 - TradingView
Kodiak Sciences Inc (KOD) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Kodiak Sciences (KOD) price target increased by 16.91% to 66.30 - MSN
KODIAK SCIENCES INC (KOD) Stock Chart - ChartMill
Kodiak Sciences (KOD) Stages a Bounce: Biotech Stock Gains 3.9% as It Tests Key ResistanceDividend Arbitrage - dars.gov.et
Is Kodiak Sciences’ (KOD) Shift Into Russell Growth Indices Reframing Its Core Investment Story? - Sahm
Form 4 Kodiak Sciences Inc For: 2 July By Investing.com - Investing.com Nigeria
Kodiak Sciences (KOD) director receives grant of 17,731 stock options - Stock Titan
Director at Kodiak Sciences (KOD) receives 17,731 stock options award - Stock Titan
[Form 4] Kodiak Sciences Inc. Insider Trading Activity - Stock Titan
17,731 options granted to Kodiak (NASDAQ: KOD) board director - Stock Titan
Kodiak Sciences (KOD) director awarded stock options for 17,731 shares at $38.96 - Stock Titan
17,731 Kodiak Sciences (KOD) options granted tied to Baker funds - Stock Titan
Kodiak Sciences Inc Q1 2026 Earnings: EPS Beat Despite Zero Revenue, Stock Gains 3.23%Earnings Call Transcript - dars.gov.et
Kodiak Sciences Inc.(NasdaqGM:KOD) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
LifeSci Capital Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Kodiak Sciences Inc.(NasdaqGM: KOD) dropped from Russell 2000 Value Benchmark - marketscreener.com
Kodiak Sciences Inc.(NasdaqGM:KOD) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Kodiak Sciences Inc.(NasdaqGM: KOD) added to Russell 2000 Growth Benchmark - marketscreener.com
Kodiak Sciences Inc.(NasdaqGM: KOD) added to Russell 3000E Growth Benchmark - marketscreener.com
Kodiak Sciences: Buy Rating Reiterated as KSI-101’s MESI Opportunity Supports Maintained $65 Price Target - TipRanks
Kodiak Sciences Inc.(NasdaqGM: KOD) dropped from Russell 3000E Index - marketscreener.com
Kodiak Sciences Inc.(NasdaqGM: KOD) dropped from Russell Microcap Index - marketscreener.com
Enterprise value to EBIT forward of Kodiak Sciences Inc – NASDAQ:KOD - TradingView
Enterprise value to EBITDA forward of Kodiak Sciences Inc – NASDAQ:KOD - TradingView
Price to book forward of Kodiak Sciences Inc – NASDAQ:KOD - TradingView
Price to sales forward of Kodiak Sciences Inc – NASDAQ:KOD - TradingView
Enterprise value to revenue forward of Kodiak Sciences Inc – NASDAQ:KOD - TradingView
Price to earnings forward of Kodiak Sciences Inc – NASDAQ:KOD - TradingView
Kodiak Sciences, Inc. Actuals & Estimates (NASDAQ:KOD) - TradingView
KOD Forecast — Price Target — Prediction for 2027 - TradingView
KODKodiak Sciences Inc Options - Finviz
Kodiak Sciences (KOD) Gains 1.2%, Approaches Key Resistance LevelOversold Bounce Ideas - dars.gov.et
Kodiak Sciences Inc (KOD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kodiak Sciences Inc (KOD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kodiak Sciences Inc (KOD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kodiak Sciences Inc (KOD) Institutional Confidence - TradingKey
Kodiak Sciences Inc (KOD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Kodiak Sciences Inc (KOD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kodiak Sciences Inc (KOD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Kodiak Sciences Inc (KOD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kodiak Sciences Inc (KOD) Valuation: PE, PB & Fair Value Analysis - TradingKey
KOD Q1 2026 Earnings: Narrowed Loss Per Share Drives 10.5% RallyRevenue Estimate Trend - DonanımHaber
KOD Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline Progress Temps Market SkepticismEarnings Decline Risk - newsline.com
Kodiak Sciences Inc Stock (US50012K1051): Quiet-day stock in focus after no fresh trigger was verifi - Ad-hoc-news.de
Kodiak Sciences: Clinical Redemption Is Turning Into Platform Leverage (NASDAQ:KOD) - Seeking Alpha
Kodiak Sciences (KOD) Edges Higher: Biotech Momentum Builds at $34.55ATR Stop - newsline.com
Kodiak stock rises 35% in 3 months: Here's what you need to know - MSN
Kodiak Sciences Inc. - MLQ.ai
Kodiak Sciences Inc Stock (KOD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):